Cantor Fitzgerald Lowers Cubist Pharmaceuticals Price Target to $63.00 (CBST)
Investment analysts at Cantor Fitzgerald reduced their target price on shares of Cubist Pharmaceuticals (NASDAQ:CBST) from $72.00 to $63.00 in a note issued to investors on Thursday, Analyst Ratings Net reports. The firm currently has a “hold” rating on the stock. Cantor Fitzgerald’s price target points to a potential downside of 0.87% from the stock’s previous close.
A number of other analysts have also recently weighed in on CBST. Analysts at Wedbush downgraded shares of Cubist Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday. They now have a $65.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Cubist Pharmaceuticals in a research note to investors on Wednesday. They now have a $69.00 price target on the stock. Finally, analysts at Jefferies Group reiterated an “in-line” rating on shares of Cubist Pharmaceuticals in a research note to investors on Wednesday. They now have a $76.00 price target on the stock, up previously from $70.00. Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $64.54.
Shares of Cubist Pharmaceuticals (NASDAQ:CBST) traded up 1.03% on Thursday, hitting $63.55. The stock had a trading volume of 2,840,363 shares. Cubist Pharmaceuticals has a 1-year low of $38.53 and a 1-year high of $66.68. The stock has a 50-day moving average of $62.68 and a 200-day moving average of $52.57. The company has a market cap of $4.200 billion and a P/E ratio of 43.47.
Cubist Pharmaceuticals (NASDAQ:CBST) last released its earnings data on Thursday, October 17th. The company reported $0.41 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.34 by $0.07. The company had revenue of $266.00 million for the quarter, compared to the consensus estimate of $267.96 million. During the same quarter last year, the company posted $0.55 earnings per share. Cubist Pharmaceuticals’s revenue was up 11.7% compared to the same quarter last year. Analysts expect that Cubist Pharmaceuticals will post $0.11 EPS for the current fiscal year.
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.